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Summary
 
Several members of the chemokine receptor family have been shown to function in association
with CD4 to permit human immunodeficiency virus type 1 (HIV-1) entry and infection. The
CXC chemokine receptor CXCR4/fusin is a receptor for pre–B cell growth stimulating factor
(PBSF)/stromal cell–derived factor 1 (SDF-1) and serves as a coreceptor for the entry of T cell
line–tropic HIV-1 strains. Thus, the development of CXCR4 antagonists or agonists may be
useful in the treatment of HIV-1 infection. T22 ([Tyr
 
5,12
 
,Lys
 
7
 
]-polyphemusin II) is a synthe-
sized peptide that consists of 18 amino acid residues and an analogue of polyphemusin II iso-
lated from the hemocyte debris of American horseshoe crabs (
 
Limulus polyphemus
 
). T22 was
found to specifically inhibit the ability of T cell line–tropic HIV-1 to induce cell fusion and in-
fect the cell lines transfected with CXCR4 and CD4 or peripheral blood mononuclear cells. In
addition, T22 inhibited Ca
 
2
 
1
 
 mobilization induced by pre–B cell growth stimulating factor
(PBSF)/SDF-1 stimulation through CXCR4. Thus, T22 is a small molecule CXCR4 inhibitor
that blocks T cell line–tropic HIV-1 entry into target cells.
 
I
 
n addition to the primary receptor for HIV-1, CD4, other
cellular factors (coreceptors) are required for HIV-1 en-
try into target cells (1–3). It was recently found that the
CXC chemokine receptor CXCR4/fusin is a coreceptor for
the entry of T cell line–tropic (T-tropic) strains of HIV-1
(4), and the CC chemokine receptor CCR5 serves as a core-
ceptor for macrophage tropic (M-tropic) strains of HIV-1
(5–9). In addition, the CXC chemokine pre–B cell growth
stimulating factor (PBSF)/stromal cell–derived factor 1
(SDF-1), recently shown to be a ligand for CXCR4, blocks
infection of lymphocytes by T-tropic HIV-1 isolates (10,
11), and the CC chemokines regulated on activation, nor-
mal T expressed and secreted (RANTES), macrophage in-
flammatory protein (MIP)-1
 
a
 
, and MIP-1
 
b
 
, which are
ligands for CCR5, inhibit infection by M-tropic HIV-1
isolates (12). These observations suggest that chemokines,
chemokine derivatives, or small molecule chemokine re-
ceptor antagonists or agonists may be useful agents for the
treatment of HIV-1 infection. It was reported that an ana-
logue of RANTES that consists of 60 amino acid residues
and acts as a CCR5 antagonist could inhibit infection by
M-tropic HIV-1 (13). However, no antagonist of CXCR4
has been reported so far. We previously found a derivative
of horseshoe crab blood cell–derived peptide, T22 ([Tyr
 
5,12
 
,
Lys
 
7
 
]-polyphemusin II), which consists of 18 amino acid resi-
dues showed strong anti-HIV-1 activity in vitro (14). Here,
we show that T22 is a small molecule CXCR4 antagonist,
and specifically inhibits the entry of T cell line–tropic HIV-1
into target cells.
 
Materials and Methods
 
Cell Lines.
 
Human osteosarcoma–derived cells (HOS) were
grown in Eagle’s MEM supplemented with 1% nonessential
amino acid (GIBCO BRL, Gaithersburg, MD) and 10% FCS.
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Human HeLaS3 cells were grown in RPMI 1640 supplemented
with 10% FCS. Mouse NIH3T3 cells and human glioma cell lines
U87MG were grown in DMEM supplemented with 10% FCS.
 
PBMCs.
 
PBMCs were obtained from healthy donors by Fi-
coll-Hypaque separation and grown in RPMI 1640 with 20%
FCS and 1 
 
m
 
g/ml PHA for 72 h. PBMCs (5 
 
3
 
 10
 
5
 
 cells) were in-
cubated with virus in 2 ml for 2 h at 37
 
8
 
C at a multiplicity of infec-
tion of 0.001. After washing residual virions, cells were resus-
pended in fresh medium containing rIL-2 (100 U/ml; Shionogi
Co., Osaka, Japan) with 20% FCS and the peptides, and the con-
centration of HIV-1 gag p24 in the culture supernatant was de-
termined by ELISA (Cellular Products, Buffalo, NY).
 
Viruses.
 
T. Shioda (University of Tokyo, Tokyo, Japan) pro-
vided us with the following panel of recombinant vaccinia vi-
ruses: Vac.Env (NL432 Env), Vac.Env JRCSF (JRCSF Env), and
Vac T4 (CD4). M. Kohara (Tokyo Metropolitan Institute of
Medical Science, Tokyo, Japan) provided us with recombinant
vaccinia viruse LO-T7 encoding the T7 polymerase. A. Adachi
(University of Tokushima, Tokushima, Japan) provided us with
HIV-1 strain NL432 (15). J.A. Levy (University of California,
San Francisco, CA) provided us with HIV-1 strain SF162 (16).
HIV-1 chimeric clone NL432
 
env-162
 
 was generated using standard
techniques by Y. Isaka (Shionogi Institute for Medical Science,
Osaka, Japan).
 
Peptides.
 
T22 and 4Ala-T-I were synthesized by Fmoc-based
solid-phase or solution-phase peptide synthesis as described previ-
ously. Murine PBSF/SDF-1 was synthesized at the Peptide Insti-
tute, Inc. (Minoo, Japan). Murine PBSF/SDF-1 has a single con-
servative Val to Ile substitution compared to the human PBSF/
SDF-1.
 
Transfection of Cell Lines.
 
NIH3T3 cells were transfected with
coreceptor in pBluescript by lipofectamine and used for fusion as-
say. U87MG and HOS cells, stably expressing human CD4 and
long terminal repeat (LTR)–
 
b
 
 galactosidase (
 
b
 
-gal) were tran-
siently transfected with 15 
 
m
 
g of coreceptor by modified calcium
phosphate method. The cells were detached with 0.5 mM
EDTA/PBS(
 
2
 
) 18 h later and passaged to 12-well plate followed
by incubation at 37
 
8
 
C overnight. The next day, cells were tested
for infection assay.
 
Cell Fusion Assays.
 
To quantitate cell–cell fusion events, we
used a modified version of the fusion assay using 
 
a
 
 complementa-
tion of 
 
b
 
-gal as reported previously. In brief, effector HeLaS3
cells (10
 
5
 
 cells/well in 24-well plates) were infected with recom-
binant vaccinia virus vectors containing the 
 
a
 
 subunit of 
 
b
 
-gal
and env proteins. Target NIH3T3 cells (5 
 
3
 
 10
 
4
 
 cells/well in 24-
well plates) were infected with the recombinant vaccinia virus
vectors containing human CD4, the 
 
v
 
 subunit of 
 
b
 
-gal and T7
RNA polymerase, and subsequently transfected with plasmids
containing coreceptors under control of the T7 promotor. 16 h
later, effector and target cells were washed with PBS containing
0.5 mM CaCl
 
2
 
 and suspended in Hanks’ balanced salt solution
containing 3 mM CaCl
 
2
 
, pH 7.6, followed by treatment with
anti–vaccinia virus antibody 2D5 in the presence or absence of
T22 peptide for 1 h. Cells were plated in 24-well plates, centri-
fuged at 1,300 rpm for 5 min, and incubated for 12 h at 37
 
8
 
C in
5% CO
 
2
 
. If fusion occurs, mixing of the cytoplasmic contents of
the cells lead to 
 
a
 
 complementation between the 
 
a
 
 and 
 
v
 
 sub-
units of 
 
b
 
-gal resulting in active enzyme. After coincubation, the
cells were lysed in 200 
 
m
 
l/well of a solution containing 8 mM of
chlorophenolred-
 
b
 
-
 
d
 
-galactopyranoside (Boehringer Mannheim,
Indianapolis, IN), 45 mM of 2-mercaptoethanol, 1 mM of
MgCl
 
2
 
, 100 mM of Hepes, pH 8.0, 0.5% NP-40, and 0.1 mg/ml
of DNAse I, and incubated for 30 min at 37
 
8
 
C. Reactions were
stopped by adding 200 
 
m
 
l/well of 2% SDS and each aliquot was
assayed for 
 
b
 
-gal activity at OD
 
590
 
.
 
Infection Assay.
 
U87MG and HOS cells were transfected with
human CD4 and an integrated HIV-1 LTR-driven reporter
gene, 
 
lacZ
 
, which is induced by the HIV-1–encoded transactivat-
ing protein Tat. Cells stably expressing human CD4 and LTR–
 
b
 
-gal were then transiently transfected with 15 
 
m
 
g of CXCR4 or
CCR5 by a modified calcium phosphate method. The cells were
plated in 12-well tissue culture plates. The next day, cells were
incubated with T22 or 4Ala-T-I peptide at 37
 
8
 
C for 1 h and in-
fected with cell-free virus stock (reverse transcriptase [RT] activ-
ity, 2 
 
3
 
 10
 
6
 
 RT/ml for SF162, and NL432
 
env162
 
, 5 
 
3
 
 10
 
6
 
 RT/ml
for IIIB, and 3 
 
3
 
 10
 
6
 
 RT/ml for NL432, 200 
 
m
 
l/well) for 2 h at
37
 
8
 
C in 5% CO
 
2
 
. After infection, 2.5 ml of culture medium was
added to each well. After 4 d of infection, cells were lysed in 400
 
m
 
l of Reporter lysis buffer (Promega Corp., Madison, WI), fol-
lowed by freezing to 
 
2
 
80
 
8
 
C and thawing. Samples were then
centrifuged at 12,000 rpm for 5 min at 4
 
8
 
C, and the supernatant
was assayed for 
 
b
 
-gal activity using Luminescent 
 
b
 
-gal Detection
Kit (Clontech, Palo Alto, CA).
 
Calcium Fluorimetry.
 
The stable CXCR4- or CCR2B-trans-
fected Chinese hamster ovary (CHO) cell lines (5 
 
3
 
 10
 
6
 
 cells)
were incubated in 1 ml of Hanks’ balanced salt solution contain-
ing 1% FCS, 10 mM Hepes, pH 7.2, and 2 
 
m
 
M of Fura-PE3 AM
for 30 min at 37
 
8
 
C. The loaded cells were washed twice with
Hanks’ balanced salt solution containing 1% FCS and 10 mM
Hepes, pH 7.2, resuspended in Hanks’ balanced salt solution con-
taining 1 mg/ml (wt/vol) of BSA and 10 mM Hepes, pH 7.2,
added to a stirred cuvette (5 
 
3
 
 10
 
6
 
 cells in 500 
 
m
 
l) and inserted
into a spectrofluorometer (LS 50B; Perkin-Elmer Corp., Nor-
walk, CT). Cells were incubated in the presence or absence of
T22 or 4Ala-T-I peptide for 2 min, and chemokines were added
in a volume of 5 
 
m
 
l at the indicated time points. Real time re-
cording of [Ca
 
2
 
1
 
]
 
i
 
 changes in the stable CXCR4- or CCR2B-
transfected CHO cell lines loaded with Fura-PE3 AM were per-
formed as described (17).
 
Results
 
First, to investigate whether T22 (Fig. 1) specifically in-
hibits HIV-1 infection mediated by CXCR4, we examined
the effect of T22 on HIV-1 infection using target cells ex-
pressing CD4 and CXCR4 or CCR5. U87MG and HOS
cells were used as target cells since these cell lines are non-
permissive for HIV-1 infection unless transfected with plas-
mid expressing human CD4 and chemokine receptors spe-
cific for particular viral strains. Target cells were infected
with T-tropic HIV-1 strains (NL432, IIIB) or M-tropic
HIV-1 strains (SF162, NL432
 
env162
 
). T-tropic HIV-1 infec-
tion to the cells expressing CXCR4 and CD4 was inhib-
ited by 0.3 
 
m
 
M T22, but not by 3 
 
m
 
M 4Ala-T-I (Fig. 1), a
control peptide that has almost the same hydrophobicity
and basic properties as T22 (Fig. 2, 
 
A
 
 and 
 
B
 
). In contrast,
Figure 1. Amino acid se-
quences of T22 and 4Ala-T-I
peptides. 
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T22 did not inhibit infection to cells expressing CCR5 and
CD4 by either M-tropic HIV-1 or a recombinant T-tropic
HIV-1 clone that has the M-tropic HIV-1 Env region.
Similar results were obtained with HOS.CD4 cells trans-
fected with either CXCR4 or CCR5 (Fig. 2, 
 
C
 
 and D).
These data indicate that T22 inhibits the T-tropic HIV-1
infection mediated by CXCR4, but not the M-tropic
HIV-1 infection mediated by CCR5.
Second, to examine whether T22 inhibits the infection
of T-tropic HIV-1 at the stage of HIV-1 Env-mediated
membrane fusion, we used a modified fusion assay as re-
ported previously (18). As shown in Fig. 3 A, membrane
fusion mediated by CXCR4 and NL432 Env was strongly
inhibited in a dose-dependent manner by 0.03–3 mM T22,
but not by the control peptide 4Ala-T-I. In contrast, T22 had
no effect on membrane fusion mediated by CCR5 and
JRCSF Env (Fig. 3 B). These results indicate that T22 in-
hibits membrane fusion mediated by CXCR4, CD4, and
T-tropic HIV-1 Env proteins.
Third, to examine whether T22 interacts with CXCR4,
we tested the effect of T22 on Ca21 mobilization induced
by PBSF/SDF-1, the ligand for CXCR4. CXCR4-express-
ing CHO cells were stimulated with PBSF/SDF-1 or mono-
cyte  chemotactic protein 1 (MCP-1) in the presence of
T22 or 4Ala-T-I, and intracellular Ca21 levels were mea-
sured. As shown in Fig. 4 A, addition of 3 mM T22 to
CXCR4 transfectants abrogated responsiveness to a subse-
quent addition of PBSF/SDF-1, whereas the same concen-
tration of T22 had no effect on Ca21 mobilization induced
by MCP-1 (Fig. 4 B). In contrast, 4Ala-T-I had no inhibi-
tory effect on Ca21 mobilization induced by either SDF-1
or MCP-1 (Fig. 4, A and B). These results indicate that
T22 is a CXCR4 inhibitor, and suggest that the interaction
of T22 with CXCR4 is involved in the suppressive effect
of T22 on T cell line–tropic HIV-1 infection.
Finally, to examine the possibility of adapting the T22 or
its counterpart as an agent for the treatment of HIV-1 in-
fection, PBMCs were used as target cells in infection assays.
As shown in Fig. 5, 0.008–0.2 mM T22 inhibited infection
by T cell line–tropic HIV-1 in a dose-dependent manner,
but not by M-tropic HIV-1 strains, indicating that T22 spe-
cifically inhibits the infection of PBMCs by T-tropic HIV-1
isolates as well as cell lines expressing CD4 and CXCR4.
Discussion
In this report, we demonstrate that T22 is a small mole-
cule CXCR4 antagonist and a potent inhibitor of infection
by T-tropic HIV-1 strains which uses CXCR4 as a core-
ceptor, but not by M-tropic HIV-1 strains, which uses
CCR5.
Figure 2. Inhibition of CXCR4-mediated HIV-1 infection by T22. (A
and B) U87MG.CD4 transfected with either CXCR4 (A) or CCR5 (B)
were incubated with the designated HIV-1 isolates in the presence of the
indicated concentrations of T22 or 4Ala-T-I. Cells were then assayed for
b-gal activity. Results are indicated as percentage of b-gal activity ob-
served in the absence of peptide. Error bars show standard deviations from
triplicate experiments. (C and D) HOS.CD4 cells expressing either
CXCR4 (C) or CCR5 (D) were infected with the indicated HIV-1 iso-
lates in the presence of T22 or 4Ala-T-I, and then assayed for b-gal activ-
ity. Results are indicated as percentage of b-gal activity compared with
that of the no peptide control samples. Error bars show standard devia-
tions from triplicate experiments.
Figure 3. Effects of T22 on
CXCR4-mediated cell fusion.
NIH3T3 target cells were trans-
fected with plasmids containing
the CXCR4 (A) or CCR5 (B)
gene driven by the T7 promoter
and coinfected with recombinant
vaccinia viruses expressing CD4,
T7 RNA polymerase, and the v
subunit of b-gal. HeLaS3 effec-
tor cells were coinfected with re-
combinant vaccinia viruses ex-
pressing the a subunit of b-gal,
and either the NL432 Env (A) or
JRCSF Env (B) proteins. Cells
were allowed to fuse in the pres-
ence of either T22 or 4Ala-T-I,
and then assayed for b-gal activ-
ity as an indicator of cell fusion.
Each value represents absorbance
per 30 min at 590 nm. Error bars
indicate standard deviations from
triplicate assays.1392 A Small Molecule CXCR4 Inhibitor that Blocks HIV-1 Infection
Our results suggest the hypothesis that binding of T22 to
CXCR4 inhibits T-tropic HIV-1 entry into target cells, al-
though we can not rule out the possibility that T22 also
binds to regions of the T-tropic HIV-1 Env protein V3 re-
gion or CD4 critical for viral entry. It has been shown that
a ligand of CXCR4 inhibits viral entry (10, 11) and that
the regions of CCR5 important for chemokine receptor
function partially overlap the regions used for viral entry by
HIV-1 (19, 20). These results support our hypothesis.
We demonstrated that T22 specifically inhibited infec-
tion by T-tropic virus strains. M-tropic virus strains are iso-
lated from individuals shortly after seroconversion and dur-
ing the asymptomatic period of the disease, appear to be
responsible for the sexual and parenteral transmission, and
represent the most prevalent phenotype. In contrast, T-tropic
HIV-1 isolates tend to appear in infected individuals at the
later stages of the infection during the transition from the
asymptomatic to the symptomatic state, and may be in-
volved in the rapid decline of CD41 T lymphocytes and
progression to AIDS. It is therefore important to find
means to inhibit CXCR4-mediated infection by T-tropic
HIV-1 in order to block progression to AIDS.
Our results showed that T22 is a CXCR4 inhibitor. Pre-
vious studies have demonstrated that agonists for CCR5,
MIP-1a, MIP-1b, and RANTES inhibit entry by M-tropic
HIV-1 isolates that use CCR5 for entry. Infection by the
subset of M-tropic isolates that use CCR3 as a coreceptor is
inhibited by eotaxin, the main CCR3 ligand. However,
high doses of such chemokines were shown to produce
harmful results by stimulating HIV-1 replication in mac-
rophages and/or intensifying virus-induced inflammation
(21). It therefore might be preferable to use antagonists
rather than agonists to avoid such side effects that may be
crucial by the latter. We recently found that a ligand for
CXCR4, PBSF/SDF-1, is essential for perinatal viability, B
lymphopoiesis, bone marrow myelopoiesis, and cardiac ven-
tricular  septal formation (22). However, it is not clear
whether blocking of the function of CXCR4 is detrimen-
tal to the adult host.
Our findings that T22 inhibited Ca21 mobilization in-
duced by PBSF/SDF-1 suggest that the structure of T22
mimics the region in PBSF/SDF-1 that is involved in the
binding to CXCR4. In fact, the CXC chemokines have a
core structure consisting of three antiparallel b sheets and
T22 also has an antiparallel b sheet structure maintained by
two disulfide bonds (23). T22 is 18 amino acids in length
and much smaller than PBSF/SDF-1. Thus, the three-dimen-
sional structure of T22 would assist in the rational design of
agents capable of inhibiting viral entry mediated by CXCR4
and the CD4–gp 120 complex.
We thank A. Sato, H. Shida, and K. Igarashi for experimental advice; A. Suyama, S. Kawauchi, S. Miki, Y.
Kataoka, and T. Iwaki for laboratory assistance; M. Lamphier (University of Tokyo, Tokyo, Japan) for his
critical review.
Supported by the Ministry of Education, Science, Sports and Culture of Japan.
Address correspondence to Naoki Yamamoto, Department of Microbiology, Tokyo Medical and Dental
University School of Medicine, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113, Japan. Phone: 81-3-5803-5178;
FAX: 81-3-5803-0124; E-mail: yamamoto.mmb@med.tmd.ac.jp
Received for publication 10 June 1997.
Figure 4. Inhibitory activities of T22 peptide on PBSF/SDF-1 induced
[Ca21]i mobilization. Stable CXCR4- (A) or CCR2B- (B) transfected
CHO cell lines were loaded with Fura-PE3 AM and treated sequentially
with either T22 or 4Ala-T-I, followed with the indicated chemokines.
Transient increases in [Ca21]i were measured using a spectrofluorometer.
PBSF/SDF-1 and MCP-1 were added at a final concentration of 100 nM,
and T22 and 4Ala-T-I were used at a final concentration of 3 mM.
Figure 5. Inhibition of HIV-1
infection in PBMCs by T22.
PHA-stimulated PBMCs from
healthy seronegative donors
were infected with either NL432
(A) or JRCSF (B) HIV-1 isolates
in the presence or absence of dif-
ferent concentrations of T22. Al-
iquots of the culture supernatant
were assayed at day 4 for HIV-1
gag p24 content by enzyme-
linked immunosorbent assay.
Results are indicated as the per-
centage of p24 content observed
in the absence of peptide. Error
bars indicate standard deviations
from triplicate assays.1393 Murakami et al. Brief Definitive Report
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